Testosterone Replacement and Cardiovascular Safety:
No Straight and Narrow!

Sartaj S. Hans¹, Sandeep S. Dhindsa² and Rama Chemitiganti²

¹Division of Cardiology, Department of Internal Medicine, University of Mississippi Medical Center, Jackson, MS, USA. ²Division of Endocrinology and Metabolism, Department of Internal Medicine, Texas Tech University Health Sciences Center – Permian Basin Campus, Odessa, TX, USA.

ABSTRACT: The past decade has seen a tremendous increase in the number of men treated for hypogonadism with the expectation of symptomatic benefit. However, the long-term cardiovascular safety of testosterone replacement remains unknown because retrospective studies of testosterone replacement have been inconsistent, and definitive, prospective, randomized studies are lacking. The purpose of this review is to critically appraise the studies on testosterone replacement and cardiovascular outcomes.

KEYWORDS: testosterone, cardiovascular disease, hypogonadism

Background
The prevalence of hypogonadism in men 45 years or older is 12%–38%, and it increases with age, BMI, and in the presence of type 2 diabetes. Longitudinal observational studies show that low testosterone concentration is associated with an increase in the incidence of cardiovascular events. Testosterone replacement therapy (TRT) favorably affects the cardio-metabolic profile with improvements in total to HDL cholesterol ratio, weight and waist circumference, insulin levels, insulin resistance, and C-reactive protein (CRP). Serum-free and total testosterone levels appear to be inversely related to the carotid intima-media thickness (a surrogate marker for atherosclerosis) with TRT, resulting in a significant decrease in thickness after 12 months of therapy. However, recently published data have posed questions about the cardiovascular safety of TRT in men with hypogonadism. This has garnered the attention of the medical community, media, and general public.

Testosterone and Atherosclerosis
Low concentration of testosterone also appears to be associated with increased atherosclerosis in elderly men (The Rotterdam Study group). Serum-free testosterone concentration is inversely related to presence and mean progression of carotid intima-media thickness of the common carotid artery in men and also with age-adjusted carotid intima-media thickness. Another line of evidence linking low testosterone concentration with cardiovascular disease comes from iatrogenically induced hypogonadism in cases of prostate cancer. Keating and colleagues studied 73,196 men with loco-regional prostate cancer treated with GnRH agonist with follow-up for up to 10 years. Patients with GnRH agonist-induced hypogonadism were more likely to have incident diabetes, coronary heart disease (CAD), myocardial infarction (MI), and sudden cardiac death.

Low Endogenous Testosterone and Mortality
Reduced testosterone concentration is common in elderly men. In 30%–50% of men above 70 years of age, free testosterone concentrations may be low. Low testosterone concentration and hypogonadism have been associated with adverse cardiovascular events and all-cause mortality in longitudinal observational studies of elderly men. In one of the earliest studies on this topic, Laughlin et al. prospectively followed 794 men aged 50–91 years (median 73.6) for 20 years in a community setting. The hazard ratio for men in the lowest quartile of testosterone level (<241 mg/dL) was 1.40 for all-cause mortality and 1.38 for cardiovascular mortality. The low testosterone–mortality association was independent of diabetes, metabolic syndrome, and prevalent cardiovascular disease. In a Swedish cohort of a large international study (Osteoporotic Fracture in Men–MrOS), 3014 men with mean age 75 years were followed for 4.5 years. Low free testosterone levels (comparison of quartile 1 with quartiles 2–4) were associated with 65% increased risk of mortality. Yeap et al. studied 3443 men aged over 70 years with median

CITATION: Hans et al. Testosterone Replacement and Cardiovascular Safety: No Straight and Narrow. Clinical Medicine Insights: Cardiology 2015:9 33–37 doi: 10.4137/CMC.23395.

RECEIVED: January 09, 2015. RESUBMITTED: February 10, 2015. ACCEPTED FOR PUBLICATION: February 21, 2015.

ACADEMIC EDITOR: Thomas E. Vanhecke, Editor in Chief

TYPE: Review

FUNDING: Authors disclose no funding sources.

COMPETING INTERESTS: SSD reports speaker’s honoraria from Abbvie. Other authors disclose no potential conflicts of interest.

CORRESPONDENCE: shans@umc.edu

COPYRIGHT: © the authors, publisher and licensee Libertas Academica Limited. This is an open-access article distributed under the terms of the Creative Commons CC-BY-NC 3.0 License.

Paper subject to independent expert blind peer review by minimum of two reviewers. All editorial decisions made by independent academic editor. Upon submission manuscript was subject to anti-plagiarism scanning. Prior to publication all authors have given signed confirmation of agreement to article publication and compliance with all applicable ethical and legal requirements, including the accuracy of author and contributor information, disclosure of competing interests and funding sources, compliance with ethical requirements relating to human and animal study participants, and compliance with any copyright requirements of third parties. This journal is a member of the Committee on Publication Ethics (COPE).

Published by Libertas Academica. Learn more about this journal.
These studies were underpowered due to very low mortality rates. On the other hand, at least two longitudinal studies did not demonstrate a relationship between low testosterone and cardiovascular mortality. These studies were performed on a much younger population (mean ages, 52 and 55 years). The lack of association may possibly be explained by the fact that these studies were underpowered due to very low mortality rates.

The available data suggest that the cause of low testosterone in elderly men is the accumulation of comorbidities with age. Healthy aged men have minimal or no decline in testosterone concentration. Studies have evaluated the association of mortality with low testosterone in men with diabetes or CAD. Ponikowska et al. followed 153 men with stable CAD and type 2 diabetes, and found that subnormal total testosterone levels were associated with 139% increased cardiovascular mortality when followed over a mean duration of 24 months of TRT. Similar findings were reported by Malkin et al. Men with CAD and a low testosterone level \((n = 930)\) at baseline had 127% excess risk for cardiovascular mortality when followed for a mean duration of 6.9 years. In contrast, a case–control study of 163 men who experienced a fatal or nonfatal MI as compared with 163 matched controls revealed no differences in the total or free testosterone levels in the two groups. A study of 581 men with type 2 diabetes \((238 \text{ with subnormal testosterone and } 343 \text{ with normal total testosterone concentration})\) found total mortality rates of 17% and 9% in men with subnormal and normal testosterone concentrations, respectively (multivariate adjusted HR of 2.02).

Given the strength of association of low testosterone concentration with mortality, it is not surprising that meta-analyses have also confirmed this association. An analysis by Araujo et al. included 11 studies of all-cause mortality (16,184 patients) with 7 studies of CV mortality (11,831 patients). Low endogenous testosterone levels were associated with increased risk of CV and all-cause mortality; however, there was significant between-study heterogeneity. A recently published meta-analysis that included 70 studies (both cross-sectional and longitudinal) also related low testosterone concentration with increased risk of cardiovascular disease and cardiovascular mortality.

Although the epidemiological data demonstrate that low endogenous testosterone concentrations in men are associated with an increased risk of CVD, it is not known whether low testosterone is merely a marker of increased risk or contributes to the cause. Thus, these observations do not demonstrate that testosterone supplementation will reduce cardiovascular risk or even that it is safe.

TRT and Cardio-Metabolic Risk Profile

Researchers used to believe that testosterone treatment adversely affects cardiovascular risk because it lowers high-density lipoprotein (HDL) cholesterol concentration. However, that effect is restricted to treatment that achieves supranormal concentrations of testosterone (eg, during abuse of androgens for body building). Testosterone has not been shown to cause any meaningful change in HDL concentration in studies where testosterone is replaced to normal levels, while many cardiovascular risk factors change favorably. The TIMES2 study investigated the effects of TRT in 220 men with hypogonadism with type 2 diabetes and/or metabolic syndrome in a multicenter, randomized, double-blind, placebo-controlled study. TRT improved insulin resistance, total and LDL cholesterol, Lp(a), body fat composition, and sexual health over a 6-month period. Haider and colleagues analyzed data from observational prospective registries for 156 obese, diabetic men on long-term TRT for hypogonadism. TRT in these individuals resulted in significant and sustained improvements in weight, waist circumference, HbA1c, total cholesterol to HDL ratio, and CRP. In a registry of seven general practices that provided TRT (long-acting testosterone undecanoate) for 30 weeks in a double-blind placebo fashion to 211 men with type 2 diabetes, TRT significantly improved HbA1c, total cholesterol, waist circumference, quality of life, and sexual function. The improvements were dependent upon achieving adequate testosterone concentrations but less marked in those with depression at baseline. Kalinchenko et al. studied 184 men with hypogonadism and metabolic syndrome to receive placebo or parenteral TRT. After 30 weeks of randomization, TRT recipients had significantly decreased in weight, waist circumference, insulin levels, and CRP. Francomano et al, in a prospective case–control study, demonstrated that TRT in patients with hypogonadism resulted in improvement of obesity, blood pressure, glycemic control, and bone mineral density. Aversa and colleagues demonstrated a significant decrease in carotid intima-media thickness after 12 months of parenteral TRT in a random-
ized, placebo-controlled trial in men with hypogonadism with metabolic syndrome.

**TRT and Cardiovascular Outcomes**

No randomized control trials (RCTs) have been conducted to examine the question: “Does TRT change cardiovascular outcomes in men?” Cardiovascular outcomes have been sporadically reported in randomized trials of TRT designed for other endpoints (such as muscle strength, glucose control, etc.), but these trials were underpowered to look at cardiac events. In the absence of robust RCTs examining the effects of TRT on long-term cardiovascular outcomes, we have to rely on currently available research. While most of the published data do not reveal an increase in MACE (major adverse cardiac event), there have been recent reports to the contrary. The following paragraphs describe the trials (prospective and retrospective) and the meta-analysis that have reported cardiovascular events after TRT.

**Randomized Control Trials**

In the Testosterone in Older Men with Mobility Limitations trial, 209 frail elderly (mean age of 74) men with low total serum testosterone levels and high prevalence of comorbidities were randomly assigned a placebo gel or testosterone gel, to be applied daily for 6 months. The trial, which was designed to determine the effects of TRT on leg strength and physical function, was halted for concerns about increased cardiovascular-“like” events (including pedal edema, which would be expected with TRT in elderly population) in the treatment group. The authors concluded that the small number and diverse adverse outcomes of variable clinical significance may have been due to chance alone. Similar investigations in elderly population assessing effects of TRT on physical function, body composition, quality of life, and other outcomes have not raised such concerns.

Trials in other populations with high cardiovascular risk (such as type 2 diabetes) have also not shown a change in rates of cardiovascular events with TRT.

**Retrospective Studies**

Shores and colleagues studied middle aged and elderly veterans with hypogonadism. They compared the total mortality rates in persons on TRT (n = 398) and those not on TRT (n = 633). In this cohort, TRT was associated with decreased mortality over the average follow-up time of more than 3 years. This effect persisted after adjustments for age and other comorbidities. Retrospective assessment of the effect of TRT on mortality in a cohort of men with hypogonadism and type 2 diabetes replicated the above findings. TRT (n = 64) was associated with reduced mortality (8.4%) as compared to 19.2% in the untreated group (n = 174). A retrospective claims-based analysis of a 5% sample of Medicare beneficiaries by Baillargeon et al compared 6,355 men aged 66 years or older who received intramuscular TRT and compared them to 19,065 who did not. TRT was not associated with an increased risk of MI (HR = 0.84; 95% CI = 0.69–1.02). Interestingly, TRT seemed to have a protective effect in men at highest risk of MI (HR = 0.69; 95% CI = 0.53–0.92).

In contrast to the above, two groups have reported the association of TRT with adverse cardiovascular outcomes. Vigen et al examined a composite outcome of all-cause mortality, MI, and stroke rates in a cohort of men with low testosterone levels who had undergone coronary angiography and subsequently received TRT. The actual reported rate of events was 10.1% for the testosterone-treated group, and 21.2% for controls, showing a reduced event rate in the treated group by more than half. However, after statistical adjustment for over 50 variables, the outcome was reversed! The use of TRT was associated with increased risk of adverse outcomes (19.9% in no treatment group vs 25.7% in treated group) 3 years after the angiography. The study has been criticized for its statistical techniques, lack of adjustment for baseline testosterone concentrations, and inadequacy of testosterone treatment in study subjects, and some corrections in actual data have been published by the authors. However, the likely explanation for the stark difference between adjusted and actual event rates is probably that the actual effect size of TRT on study points was much smaller than the effect of comorbidities that needed adjustment among mismatched groups. In another study, Finkle and colleagues examined 55,593 insurance claims and compared the incidence of rate of MI in the one year prior and 90 days after initial prescription of TRT. They reported an increased rate of nonfatal MIs especially in men aged 65 or older. In men younger than 65 years, the risk was confined to those with preexisting heart disease. There was no control group. The strategy of comparison of pre- and post-prescription event rates is fraught with confounders. Most practitioners prescribe TRT to increase libido and energy levels in men. Diagnosing hypogonadism and prescribing TRT is usually a low priority in a man with recent MI. Thus, it would be expected that the pre-prescription period would selectively include men without a history of MI, resulting in falsely low rates. The increase in MI over the duration of the study can be partially explained by the continuing accumulation of events in a “high cardiovascular risk” population. In fact, the event rates in the study were approximately one-third of what would be expected in a group of men with mean age of 54 years (average age of study participants). There was no information available on testosterone concentrations (pre or post treatment) or of cardiovascular risk factors in subjects who were treated. Furthermore, the treatment duration of 3 months is wholly inadequate for a trial looking at cardiac events. This is in contrast to the above-mentioned insurance-claims-based analysis by Baillargeon et al.

**Meta-Analyses**

Multiple meta-analyses have evaluated the effect of TRT on cardiovascular events. A recent meta-analysis by
Corona and colleagues, included 75 randomized placebo-controlled trials of TRT, evaluated the incidence of MACE where available.50 They reported no association between the TRT and placebo groups even after accounting for variables such as funding source, age at treatment, and other chronic diseases. This lack of association between cardiovascular events and TRT concurs with the results of all the other meta-analyses except the one by Xu et al.49 They report that TRT increased the cardiovascular-related event risk in studies not funded by pharmaceutical companies. The data available from six RCTs35–39 with cardiovascular outcomes were analyzed by Corona et al.50 These were heterogeneous trials with patients with preexisting coronary heart disease (CHD), which enrolled 258 patients and showed improvements in exercise capabilities (significant increase in treadmill test duration and time to 1-mm ST segment depression). These trials enrolled persons with varying basal T rates, and used different T supplements.

The U.S. Food Drug Administration (FDA) in its recent denial of the citizen petition to make changes to the safety labeling of TRT provides a detailed analysis of methodological deficiencies of all the studies that show association with adverse cardiovascular events.56 The Testosterone Trial, funded by the National Institutes of Health (NIH), will test the hypothesis that testosterone treatment in men older than 65 and unequivocally low serum testosterone concentration compared to placebo treatment will improve their physical function, sexual function, vitality, cognitive function, and low hemoglobin concentration, and decrease risk factors for CVD and diabetes. The results of this study will add to our understanding of TRT. However, it is not powered to provide data that will resolve the controversy of TRT and cardiovascular outcomes.57

Conclusion

Epidemiological data show an association of hypogonadism and decreased survival. It seems intuitive, then, that TRT in men with hypogonadism would lead to improved cardiovascular outcomes. However data on this are a mixed bag. Low testosterone concentrations may merely be a marker of a chronic systemic inflammatory state involving the hypothalamic-pituitary–gonadal axis rather than the agent modulating adverse cardiovascular outcomes. TRT is beneficial for patients suffering from symptoms of hypogonadism and probably is safe for use based on current evidence. TRT should be initiated in appropriate patients, maintained, and monitored subsequently using standardized plans.58 Further research should be conducted to understand the effect of TRT on mechanisms that underlie atherosclerosis and cardiovascular events. Appropriately powered trials of TRT that evaluate MACE should be carried out in “at-risk populations”, such as type 2 diabetes and metabolic syndrome. If these trials show a benefit of TRT on MACE, then it is likely that a large trial on TRT and elderly men with MACE reduction as primary endpoint would be funded.

Author Contributions

Analyzed the data: SH, SD, RC. Wrote the first draft of the manuscript: SH, RC. Contributed to the writing of the manuscript: SD. Agree with manuscript results and conclusions: SH, SD, RC. Jointly developed the structure and arguments for the paper: SH, SD. Made critical revisions and approved final version: SH, SD, RC. All authors reviewed and approved of the final manuscript.

REFERENCES

1. Mulligan T, Frick MF, Zuraq QC, Stenhagen A, McWhirter C. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract. 2006;60(7):762–9.
2. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab. 2001;86(2):724–31.
3. Dhindsa S, Miller MG, McWhirter CL, et al. Testosterone concentrations in diabetic and nondiabetic obese men. Diabetes Care. 2010;33(6):1186–92.
4. Laughlin GA, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab. 2008;93(1):68–75.
5. Trevenen A, Vandenuur F, Labrie F, et al. Low serum testosterone and estradiol predict mortality in elderly men. J Clin Endocrinol Metab. 2009;94(7):2488–92.
6. Yeap BB, Hyde Z, Almeida OP, et al. Lower testosterone levels predict incident stroke and transient ischemic attack in older men. J Clin Endocrinol Metab. 2009;94(7):2353–9.
7. Malker CJ, Pugh PJ, Morris PD, Asif S, Jones TH, Channer KS. Low serum testosterone and increased mortality in men with coronary heart disease. Heart. 2010;96(22):1821–5.
8. Baillargeon J, Urban RJ, Kuo YF, et al. Risk of myocardial infarction in older men receiving testosterone therapy. Ann Pharmacother. 2014;48(9):1138–44.
9. Jones TH, Arver S, Behre HM. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care. 2011;34(4):828–37.
10. Kalincsenko SY, Tishova YA, Mikhailyga JF, Gooren LJ, Gilayt EJ, Saad F. Effects of testosterone supplementation on markers of the metabolic syndrome in male patients with type 2 diabetes. J Intern Med. 2010;268(2):199–209.
11. Fukui M, Kitagawa Y, Nakamura N, et al. Association between serum testosterone concentration and carotid atherosclerosis in men with type 2 diabetes. Diabetes Care. 2003;26(6):1869–73.
12. Svarberg J, von Muhlen D, Mathiesen E, Joksimns O, Bonaa KH, Stensland-Bugg E. Low testosterone levels are associated with carotid atherosclerosis in men. J Intern Med. 2006;259(6):576–92.
13. Fatias JM, Tinetti M, Khoury M, Umpierrez GE. Low testosterone concentration and atherosclerotic disease markers in male patients with type 2 diabetes. J Clin Endocrinol Metab. 2014;99(12):4069–703.
14. Aversa A, Bruzziches R, Franchomano D, et al. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study. J Sex Med. 2010;7(10):3495–503.
15. Hak AE, Witterman JC, de Jong FH, Geerlings MI, Hofman A, Pols HA. Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam study. J Clin Endocrinol Metab. 2002;87(8):3632–9.
16. Muller M, van den Beld AW, Bots ML, Grobbee DE, Lamberts SW, van der Schouw YT. Endogenous sex hormones and progression of carotid atherosclerosis in elderly men. Circulation. 2004;109(17):2074–9.
17. Keating NL, O’Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24(27):4448–56.
18. Yeap BB, Alfonso H, Chubb SA, et al. In older men an optimal plasma testosterone one is associated with reduced all-cause mortality and higher dihydrotestosterone with reduced ischemic heart disease mortality, while estradiol levels do not. J Sex Med. 2010;7(10):3495–503.
19. Haring R, Volzke H, Steveling A, et al. Low serum testosterone levels are associated with increased risk of mortality in a population-based cohort of men aged 20–79. Eur Heart J. 2010;31(12):1944–501.
20. Hyde Z, Norman PD, Flicker L, et al. Low free testosterone predicts mortality from cardiovascular disease but not other causes: the Health in Men Study. J Clin Endocrinol Metab. 2012;97(1):179–89.
21. Khaw KT, Dowsett M, Folkert E, et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospecive investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation. 2007;116(23):2694–701.

22. Vikan T, Johnsen SH, Schirmer H, Njoehtad I, Svatberg J. Endogenous testosterone and the prospective association with carotid atherosclerosis in men: the Tromso study. Eur J Epidemiol. 2009;24(6):289–95.

23. Shores MM, Matsumoto AM, Sloan KL, Knivlahan DR. Low serum testosterone and mortality in male veterans. Arch Intern Med. 2006;166(15):1660–5.

24. Araujo AB, Kupelian V, Page ST, Handelmann DJ, Brenner WJ, McKinlay JB. Sex steroids and all-cause and cause-specific mortality in men. Arch Intern Med. 2007;167(12):1252–60.

25. Smith GD, Ben-Shlomo Y, Beswick A, Yarnell J, Lightman S, Elwood P. Correlates of endogenous testosterone and mortality in men 1990–2010. BMJ. 2011;342:d1924.

26. Ponikowska B, Jankowska EA, Maj J, et al. Gonadal and adrenal androgen deficiencies as independent predictors of increased cardiovascular mortality in men with type II diabetes mellitus and stable coronary artery disease. Int J Cardiol. 2010;139(2):277–84.

27. Cauley JA, Guralnik J, Kuller LH, Dai WS. Usefulness of sex steroid hormone levels in predicting coronary artery disease in men. Am J Cardiol. 1987;60(10):771–7.

28. Muraleedharan V, Marsh H, Kapoor D, Channer KS, Jones TH. Testosterone undecanoate on metabolic and hormonal parameters in ageing men with type 2 diabetes. J Clin Endocrinol Metab. 2010;95:2560–75.

29. Araujo AB, Dixon JM, Suarez EA, Murad MH, Guay LT, Wittert GA. Clinical review: endogenous testosterone and mortality in men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2011;96(10):3007–17.

30. Corona G, Rastrelli G, Monami M, et al. Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. Eur J Endocrinol. 2011;165(5):673–81.

31. Fernandez-Balsells MM, Murad MH, Lane M, et al. Clinical review 1: adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2013;98(6):2523–35.

32. Hartert TV, Glaister S, Brindley P, et al. Meta-analyses in obese hypogonadal men with type 2 diabetes. Int J Androl. 2014;37(8):2098–107.

33. Hackett G, Cole N, Bhartia M, Kennedy CC, Caples SM, et al. Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of placebo-controlled trials. Mayo Clin Proc. 2007;82:29–39.

34. Xu L, Freeman G, Cowling BJ, Schooling CM. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled trials. Mayo Clin Proc. 2014;89(3):336–50.

35. Corrao G, Maserei L, Rastrelli G, et al. Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis. Expert Opin Drug Saf. 2014;13:1327–31.

36. Morgenthaler A, Talkowski MJ, Haack DH, et al. Effect of acute testosterone on myocardial ischemia in men with coronary artery disease. Am J Cardiol. 1999;83:437–9.

37. English KM, Steeds RP, Jones TH, Diver MJ, Channer KS. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: a randomized, double-blind, placebo-controlled study. Circulation. 2002;106:1906–11.

38. Thompson PD, Alhberg AW, Moyna NM, et al. Effect of intravenous testosterone on myocardial ischemia in men with coronary artery disease. Am Heart J. 2002;143:249–56.

39. Malik CN, Pugh PJ, Morris PD, et al. Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life. Heart. 2004;90:871–6.

40. Snyder PJ, Peachev H, Hannoun P, et al. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab. 1999;84:2647–53.

41. Gianaati EJ, Dupuis P, Hoermann R, et al. Effect of testosterone treatment on glucose metabolism in men with type 2 diabetes: a randomized controlled trial. Diabetes Care. 2014;37(10):e107–10.

42. Shores MM, Smith NL, Forsberg CW, Anawalt BD, Matsumoto AM. Testosterone treatment and mortality in men with low testosterone levels. J Clin Endocrinol Metab. 2012;97(6):2505–8.

43. Vigen R, O’Donnell CI, Barin AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013;310:1829–36.

44. Finkle WD, Greenland S, Ridgeway GK, et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One. 2014;9:e83805.

45. Morgenthaler A, Miner MM, Caliber M, Guay AT, Khera M, Traish AM. Testosterone therapy and cardiovascular risk: advances and controversies. May Clin Proc. November 1, 2014. pii: S0025­6196(14)00925­2. doi: 10.1016/j.mayocp.2014.10.011. [Epub ahead of print].

46. Morgenthaler A. Testosterone deficiency and cardiovascular mortality. Asian J Andrrol. 2015;17(1):26–31. doi: 10.4103/1008–682X.143248.

47. Calof OM, Singh AB, Lee M, et al. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A: Biol Sci Med Sci. 2005;60:1461–7.

48. Haddad RM, Kennedy CC, Caples SM, et al. Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of placebo-controlled trials. Mayo Clin Proc. 2007;82:29–39.

49. Robson AM, Adamson DL, de Zegher D, Collins P. Effect of acute testosterone on myocardial ischemia in men with coronary artery disease. Am J Cardiol. 1999;83:437–9.

50. Mathur A, Malkin C, Bhatia M, Kennedy CC, Caples SM, et al. Testosterone and cardiovascular risk in men with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Circulation. 2002;106:1906–11.

51. Thompson PD, Alhberg AW, Moyna NM, et al. Effect of intravenous testosterone on myocardial ischemia in men with coronary artery disease. Am Heart J. 2002;143:249–56.

52. Malik CN, Pugh PJ, Morris PD, et al. Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life. Heart. 2004;90:871–6.

53. Mathur A, Malkin C, Bhatia M, Kennedy CC, Caples SM, et al. Testosterone and cardiovascular risk in men with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Circulation. 2002;106:1906–11.

54. Thompson PD, Alhberg AW, Moyna NM, et al. Effect of intravenous testosterone on myocardial ischemia in men with coronary artery disease. Am Heart J. 2002;143:249–56.

55. Malkin C, Pugh PJ, Morris PD, et al. Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life. Heart. 2004;90:871–6.

56. The U.S. Food and Drug Administration (FDA) response to citizen petition (Re:FDA-2014-P-0258) 07/2014. http://www.citizen.org/documents/2184_FDA%20Denial%20of%20Petition_July%2016,%202014.pdf

57. About the Testosterone Trial. Available at: http://r5.ceb.umn.edu/portal/page/portal/T­Trials92­Portal/T­Trial92­Public­%20Page%20­-%20About. Accessed December 15, 2014. Publication year 2014.